# US 2004/0082037 A1 · Growth arrest homeobox gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082037 A1
- Document ID: US20040082037A1
- Status: Published application
- Kind: A1
- Application number: 10/638,709
- Filed: 2003-08-11
- Published: 2004-04-29
- Earliest claimed: 1994-02-24
- Inventors: David H. Gorski; Kenneth Walsh
- Web page: https://patentgrep.com/patent/US20040082037A1

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A novel growth arrest homeobox gene has been discovered and the nucleotide sequences have been determined in both the rat and the human. The expression of the novel homeobox gene inhibits vascular smooth muscle cell growth. The growth arrest homeobox gene hereinafter referred to as the “Gax gene” and its corresponding proteins are useful in the study of vascular smooth muscle cell proliferation and in the treatment of blood vessel diseases that result from excessive smooth muscle cell proliferation, particularly after balloon angioplasty.

## Claims

### Claim 1

A DNA sequence encoding a protein or portion thereof, which inhibits vascular smooth muscle cell proliferation.

### Claim 2 (depends on 1)

The DNA sequence of claim 1, comprising the nucleotide sequence substantially as shown in FIG. 1.

### Claim 3 (depends on 1)

The DNA sequence of claim 1, comprising the nucleotide sequence substantially as shown in FIG. 3.

### Claim 4 (depends on 1)

The DNA sequence of claim 1, comprising the nucleotide sequence from about 200 to about 1108 substantially as shown in FIG. 1.

### Claim 5 (depends on 1)

The DNA sequence of claim 1, comprising the nucleotide sequence from about 749 to about 919 substantially as shown in FIG. 1.

### Claim 6 (depends on 1)

The messenger RNA transcript of the DNA of claim 1.

### Claim 7

An isolated protein which inhibits vascular smooth muscle cell growth.

### Claim 8 (depends on 7)

The protein of claim 7 having a molecular weight of from about 30 kDA to about 36 kDa.

### Claim 9 (depends on 7)

The protein of claim 7, comprising the amino acid sequence substantially as shown in FIG. 1.

### Claim 10 (depends on 7)

The protein of claim 7, comprising the amino acid sequence substantially as shown in FIG. 3.

### Claim 11 (depends on 7)

The protein of claim 7, comprising the amino acid sequence from about 1 to about 303 substantially as shown in FIG. 1.

### Claim 12 (depends on 7)

The protein of claim 7, further comprising glutathione S-transferase.

### Claim 13 (depends on 1)

A vector containing the DNA sequence of claim 1.

### Claim 14 (depends on 2, 13)

The vector of claim 13, wherein the nucleotide sequence is the nucleotide sequence of claim 2.

### Claim 15 (depends on 3, 13)

The vector of claim 13, wherein the nucleotide sequence is the nucleotide sequence of claim 3.

### Claim 16 (depends on 4, 13)

The vector of claim 13, wherein the nucleotide sequence is the nucleotide sequence of claim 4.

### Claim 17 (depends on 5, 13)

The vector of claim 13, wherein the nucleotide sequence is the nucleotide sequence of claim 5.

### Claim 18 (depends on 13)

A host cell transformed by vector of claim 13 containing the nucleotide sequence coding for Gax protein.

### Claim 19 (depends on 14)

A host cell transformed by vector of claim 14 containing the nucleotide sequence coding for Gax protein.

### Claim 20 (depends on 15)

A host cell transformed by vector of claim 15 containing the nucleotide sequence coding for Gax protein.

### Claim 21 (depends on 16)

A host cell transformed by vector of claim 16 containing the nucleotide sequence encoding the Gax protein.

### Claim 22 (depends on 17)

A host cell transformed by vector of claim 17 containing the nucleotide sequence encoding the Gax protein.

### Claim 23 (depends on 18)

A process for the preparation of Gax protein comprising culturing the transformed host of claim 18 under conditions suitable for the expression of Gax protein and recovering the Gax protein.

### Claim 24 (depends on 19)

A process for the preparation of a protein which inhibits the proliferation of vascular smooth muscle cells comprising culturing the transformed host of claim 19 under conditions suitable for the expression of the protein and recovering the protein.

### Claim 25 (depends on 20)

A process for the preparation of a protein which inhibits the proliferation of vascular smooth muscle cells comprising culturing the transformed host of claim 20 under conditions suitable for the expression of the protein and recovering the protein.

### Claim 26 (depends on 21)

A process for the preparation of a protein which inhibits the proliferation of vascular smooth muscle cells comprising culturing the transformed host of claim 21 under conditions suitable for the expression of the protein and recovering the protein.

### Claim 27 (depends on 23, 24, 25, 26)

The Gax protein made by the process selected from the processes of claim 23, claim 24, claim 25, and claim 26.

### Claim 28

A method for inhibiting the proliferation of eukaryotic cells, comprising the following steps:
a. providing nucleic acid sequence encoding a protein, or portion thereof, which inhibits vascular smooth muscle cell proliferation; and
b. administering said nucleic acid or said protein to the cells.

### Claim 29 (depends on 28)

The method of claim 28 wherein the nucleic acid is DNA.

### Claim 30 (depends on 28)

The method of claim 28 wherein the nucleic acid is RNA.

### Claim 31 (depends on 28)

The method of claim 28 wherein the protein comprises the amino acid sequence from about 1 to 303 shown in FIG. 1.

### Claim 32 (depends on 28)

The method of claim 28 wherein the cells are vascular smooth muscle cells.
